We recently
started to work with Consilium and immediately they became a vital part of
iSonea's team. The Consilium analyst’s understanding of investor markets
has been invaluable across a range of issues and
opportunities. Consilium's understanding of our business and industry also
contributed to it becoming a trusted associate that was integral in
helping design our strategic direction. Two of Consilium's greatest assets are
its knowledge of Wall Street and its ability to focus companies on the issues
most relevant.
Michael J
Thomas - CEO, iSonea Ltd
Consilium’s
expertise in health care and its ability to communicate our corporate
achievements and potential in a useful format for the investment community has
been valuable and much appreciated. From day one, they were able to clarify our
business strategies without over simplifying the facts. Additionally, they
have numerous buy side relationships to help cultivate our success with Wall
Street.
Bryan
Dulhunty - Managing Director & CEO, Viralytics Ltd
Consilium
Global Research recently wrote a comprehensive research report of Neogenix
Oncology and we were extremely pleased with the final result. The report
provided an in-depth yet balanced examination of our company, presenting what is
a complicated story in a manner that is more lucid and informative to our
investors. Consilium is a group of highly experienced Wall St. analysts and that
experience was self evident in our ongoing discussions with them and in the
preparation of their report.
Peter
Gordon, CFO, Neogenix Oncology
